Glutathione, iron and Parkinson's disease

Biochemical Pharmacology

Volumn 64, Issue 5-6, 2002, Pages 1037-1048

  Bharath, Srinivas ^a   Hsu, Michael ^a   Kaur, Deepinder ^a   Rajagopalan, Subramanian ^a   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Glutathione; Iron; Lewy bodies; Mitochondrial dysfunction; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 HYDROXYNONENAL; ALPHA SYNUCLEIN; CATALASE; CYTOCHROME C OXIDASE; DOPAMINE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE ISOPROPYL ESTER; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN; IRON; OXIDOPAMINE; PARKIN; PROTEASOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROTENONE; SUPEROXIDE DISMUTASE; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUITIN;

ARTICLE; CYTOPLASM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUTATHIONE METABOLISM; HUMAN; LEWY BODY; MITOCHONDRION; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SEQUENCE HOMOLOGY;

ANTIOXIDANTS; BRAIN; GLUTATHIONE; HUMANS; IRON; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0036710567     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01174-7     Document Type: Article

References (146)

1. Youdim M.B., Riederer P. Understanding Parkinson's disease. Sci. Am. 276:1997;52-59.
2. Schoenberg B.S. Descriptive epidemiology of Parkinson's diseases: distribution and hypothesis formulation. Adv. Neurol. 45:1986;277-283.
3. Jankovic J. Pathophisiology and clinical assessment of motor symptoms in Parkinson's Disease. In: Koller WC, editor. Handbook of Parkinson's disease. New York: Dekker, 1992. p. 129-57.
4. Burke RE. Parkinson's Disease, Cell Death and Disease of the Nervous System. In: Koliatos VE, Rattan RR, editors. Totowa, NJ: Humana Press Inc., 1998. p. 459-75.
5. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272.
6. Adams J.D. Jr., Chang M.L., Klaidman L.K. Parkinson's disease - redox mechanisms. Curr. Med. Chem. 8:2001;809-814.
7. Cohen G.M., d'Arcy Doherty M. Free radical mediated cell toxicity by redox cycling chemicals. Br. J. Cancer. 8(Suppl):1987;46-52.
8. Pugliese P.T. The skin's antioxidant systems. Dermatol. Nurs. 10:1998;401-416.
9. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
10. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994;92-97.
11. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2696-2701.
12. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-203.
13. Graham D.G. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology. 5:1984;83-95.
14. Andersen J.K., Frim D.M., Isacson O., Beal M.F., Breakefield X.O. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res. 656:1994;108-114.
15. Double K.L., Gerlach M., Youdim M.B., Riederer P. Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. Suppl. 60:2000;37-58.
16. Sies H. Glutathione and its role in cellular functions. Free Radic. Biol. Med. 27:1999;916-921.
17. Meister A., Anderson M.E. Glutathione. Ann. Rev. Biochem. 52:1983;711-760.
18. Dringen R., Gutterer J.M., Hirlinger J. Glutathione metabolism in the brain. Eur. J. Biochem. 267:2000;4912-4916.
19. Arrigo A.P. Gene expression and thiol redox state. Free Radic. Biol. Med. 27:1999;945-951.
20. Sen CK, Sies H, Baeuerle PA. Antioxidant and Redox Regulation of Genes. San Diego: Academic Press, 1999.
21. Hall A.G. The role of glutathione in the regulation of apoptosis. Eur. J. Clin. Invest. 29:1999;238-254.
22. Ji Y., Akerboom T.P.M., Sies H., Thomas J.A. S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione. Arch. Biochem. Bipohys. 362:1999;67-78.
23. Hausladen A., Stamler J.S. Nitrosative stress. Methods Enzymol. 300:1999;389-395.
24. Lomaestro B.M., Malone M. Glutathione in health and disease, pharmaco-therapuetic issues. Ann. Pharmacother. 29:1995;1263-1273.
25. Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative-stress mediated neuronal death. Brain. Res. Brain. Res. Rev. 25:1997;335-358.
26. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 27:1999;922-935.
27. Dringen R. Metabolism and functions of glutathione in the brain. Prog. Neurobiol. 62:2000;649-671.
28. Salinas A.E., Wong M.G. Glutathione-S-trasferases - a review. Curr. Med. Chem. 6:1999;279-309.
29. Akerboom TPM, Sies H. Glutathione transport and its significance in oxidative stress. In: Vina J, editor. Glutathione: Metabolism and Physiological Functions. Boca Raton, FL: CRC Press, 1990. p. 45-55.
30. Kaplowitz N., Fernandez-Checa J.C., Kannan R., Garcia-Ruiz C., Ookhtens M., Yi J.R. GSH transporters: molecular characterization and role in GSH homeostasis. Biol. Chem. 377:1996;267-273.
31. Shi Z.Z., Osei-Frimpong J., Kala G., Kala S.V., Barrios R.J., Habib G.M., Lukin D.J., Danney C.M., Matzuk M.M., Lieberman M.W. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5101-5106.
32. Klivenyi P., Andreassen O.A., Ferrante R.J., Dedeoglu A., Mueller G., Lancelot E., Bogdanov M., Andersen J.K., Jiang D., Beal M.F. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20:2000;1-7.
33. Subramaniam R., Roediger F., Jordan B., Mattson M.P., Keller J.N., Waeg G., Butterfield D.A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69:1997;1161-1169.
34. Chen J.J., Yu B.P. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radic. Biol. Med. 17:1994;411-418.
35. Chen J.J., Yu B.P. Detoxification of reactive aldehydes in mitochondria: effects of age and dietary restriction. Aging (Milano). 8:1996;334-340.
36. Wolf S., Gassen H.G. Gamma-glutamyl transpeptidase, a blood-brain barrier associated membrane protein. Splitting peptides to transport amino acids. Adv. Exp. Med. Biol. 421:1997;37-45.
37. Sian J., Dexter D.T., Lees A.J., Daniel S.E., Jenner P., Marsden C.D. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36:1994;356-361.
38. Clark DD, Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel GJ, Agranoff, BW, Albers RW, Fisher SK, Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia: Lippincott-Raven, 1994. p. 637-69.
39. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
40. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
41. Kannan R., Kuhlenkamp J.F., Ookhtens M., Kaplowitz N. Transport of glutathione at blood-brain barrier of the rat: inhibition by glutathione analogs and age-dependence. J. Pharmacol. Exp. Ther. 263:1992;964-970.
42. Kannan R., Mittur A., Bao Y., Tsuruo T., Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. J. Neurochem. 73:1999;390-399.
43. Philbert M.A., Beiswanger C.M., Waters D.K., Reuhl K.R., Lowndes H.E. Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthaldialdehyde-induced histofluorescence. Toxicol. Appl. Pharmacol. 107:1991;215-227.
44. Maybodi L., Pow D.V., Kharazia V.N., Weinberg R.J. Immunocytochemical demonstration of reduced glutathione in neurons of rat forebrain. Brain Res. 817:1999;199-205.
45. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur. J. Biochem. 267:2000;4912-4916.
46. Orwar O., Li X., Andine P., Bergstrom C.M., Hagberg H., Folestad S., Sandberg M. Increased intra- and extracellular concentrations of gamma-glutamylglutamate and related dipeptides in the ischemic rat striatum: involvement of glutamyl transpeptidase. J. Neurochem. 63:1994;1371-1376.
47. Lada M.W., Kennedy R.T. In vivo monitoring of glutathione and cysteine in rat caudate nucleus using microdialysis on-line with capillary zone electrophoresis-laser induced fluorescence detection. J. Neurosci. Methods. 72:1997;153-159.
48. Yang C.S., Chou S.T., Lin N.N., Liu L., Tsai P.J., Kuo J.S., Lai J.S. Determination of extracellular glutathione in rat brain by microdialysis and high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl. 661:1994;231-235.
49. Janaky R., Ogita K., Pasqualotto B.A., Bains J.S., Oja S.S., Yoneda Y., Shaw C.A. Glutathione and signal transduction in the mammalian CNS. J. Neurochem. 73:1999;889-902.
50. Sohal R.S., Weindruch R. Oxidative stress, caloric restriction and aging. Science. 273:1996;59-63.
51. Cudkowisz M.E., Sexton P.M., Ellis T., Hayden T.L., Gwilt P.R., Whalen J., Brown R.H. Jr. The pharmacokinetics and pharmacodynamics of procysteine in amyotropic lateral sclerosis. Neurology. 52:1999;1492-1494.
52. Chen T.S., Richie J.P. Jr., Lang C.A. The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc. Soc. Exp. Biol. Med. 190:1989;399-402.
53. Hussain S., Slickker W. Jr., Ali S.F. Age related changes in anti-oxidant enzymes, superoxide dismutase, catalase, glutathione peroxidase and glutathione in different regions of the mouse brain. Int. J. Dev. Neurosci. 13:1995;811-817.
54. Kang Y., Viswanath V., Jha N., Qiao X., Mo J.Q., Andersen J.K. Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. J. Neurosci. Res. 58:1999;436-441.
55. Abbott L.C., Nejad H.H., Bottje W.G., Hassan A.S. Glutathione levels in specific brain regions of genetically epileptic (tg/tg) mice. Brain Res. Bull. 25:1990;629-631.
56. Chen T.S., Richie J.P. Jr., Lang C.A. The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc Soc. Exp. Biol. Med. 190:1989;399-402.
57. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
58. Sofic E., Lange K.W., Jellinger K., Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:1992;128-130.
59. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67:1986;269-274.
60. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand. Suppl. 146:1993;6-13.
61. Andersen J.K., Mo J.Q., Hom D.G., Lee F.Y., Harnish P., Hamill R.W., McNeill T.H. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J. Neurochem. 67:1996;2164-2171.
62. Wullner U., Loschmann P.A., Schulz J.B., Schmid A., Dringen R., Eblen F., Turski L., Klockgether T. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. Neuroreport. 7:1996;921-923.
63. Pileblad E., Magnusson T., Fornstedt B. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J. Neurochem. 52:1989;978-980.
64. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural. Transm. Suppl. 59:2000;133-154.
65. Heales S.J., Davies S.E., Bates T.E., Clark J.B. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem. Res. 20:1995;31-38.
66. Martinez M., Ferrandiz M.L., Diez A., Miquel J. Depletion of cytosolic GSH decreases the ATP levels and viability of synaptosomes from aged mice but not from young mice. Mech. Ageing Dev. 84:1995;77-81.
67. Zhang Y., Marcillat O., Giulivi C., Ernster L., Davies K.J. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J. Biol. Chem. 265:1990;16330-16336.
68. Hillered L., Chan P.H. Effects of arachidonic acid on respiratory activities in isolated brain mitochondria. J. Neurosci. Res. 19:1988;94-100.
69. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-30.
70. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722.
71. Lenaz G., Bovina C., Castelluccio C., Fato R., Formiggini G., Genova M.L., Marchetti M., Pich M.M., Pallotti F., Parenti Castelli G., Biagini G. Mitochondrial complex I defects in aging. Mol. Cell Biochem. 174:1997;329-333.
72. Davey G.P., Peuchen S., Clark J.B. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 273:1998;12753-12757.
73. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J. Biol. Chem. 275:2000;26096-26101.
74. Keyer K., Imlay J.A. Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13635-13640.
75. Ziegler D.M. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Ann. Rev. Biochem. 54:1985;305-329.
76. Ravindranath V., Reed D.J. Glutathione depletion and formation of glutathione-protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem. Biophys. Res. Commun. 169:1990;1075-1079.
77. Fornstedt B., Bergh I., Rosengren E., Carlsson A. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J. Neurochem. 54:1990;578-586.
78. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 93:1996;1956-1961.
79. Sriram K., Shankar S.K., Boyd M.R., Ravindranath V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J. Neurosci. 18:1998;10287-10296.
80. Liochev S.L. The role of iron-sulfur clusters in in vivo hydroxyl radical production. Free Radic. Res. 25:1996;369-384.
81. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry. 20:1996;1159-1170.
82. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutka S.J., Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 376:1986;117-124.
83. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1316.
84. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
85. Sinha B.K., Singh Y., Krishna G. Formation of superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P-450 reductase. Biochem. Biophys. Res. Commun. 135:1986;583-588.
86. Chacon J.N., Chedekel M.R., Land E.J., Truscott T.G. Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenyl-pyridinium ion. Biochem. Biophys. Res. Commun. 144:1987;957-964.
87. Adams J.D. Jr., Klaidman L.K., Leung A.C. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 15:1993;181-186.
88. Halliwell B., Gutteridge J.M. The importance of free radicals and catalytic metal ions in human diseases. Mol. Aspects Med. 8:1985;89-193.
89. Bannon M.J., Goedert M., Williams B. The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. Biochem. Pharmacol. 33:1984;2697-2698.
90. Andersen JK. What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease? Mech Ageing Dev 2000;118:15-22.
91. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
92. de Silva H.R., Khan N.L., Wood N.W. The genetics of Parkinson's disease. Curr. Opin. Genet. Dev. 10:2000;292-298.
93. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. N. Y. Acad. Sci. 920:2000;28-32.
94. Lev N., Melamed E. Heredity in Parkinson's disease: new findings. Isr. Med. Assoc. J. 3:2001;435-438.
95. Hershko A., Ciechanover A. The ubiquitin system. Ann. Rev. Biochem. 67:1998;425-479.
96. Gasser T. Genetics of Parkinson's disease. Ann. Neurol. 44:1998;S53-S57.
97. Rajagopalan S., Andersen J.K. Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? Mech. Ageing Dev. 122:2001;1499-1510.
98. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
99. Jha N., Kumar J.M., Boonplueang R., Andersen J.K. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease? J. Neurochem. 80:2002;555-561.
100. Freyaldenhoven T.E., Ali S.F., Hart R.W. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688:1995;161-170.
101. Li H., Dryhurst G. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69:1997;1530-1541.
102. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74:1988;199-205.
103. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982.
104. Dexter D.T., Wells F.R., Lees A.J., Javoy-Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
105. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain. 122:1999;667-673.
106. Riederer P., Dirr A., Goetz M., Sofic E., Jellinger K., Youdim M.B. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 32(Suppl):1992;S101-S104.
107. Becker G., Seufert J., Bogdahn U., Reichmann H., Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 45:1995;182-184.
108. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., Benz P., Jost W., Reiners K., Lange K.W. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 53:1999;1026-1031.
109. Ryvlin P., Broussolle E., Piollet H., Viallet F., Khalfallah Y., Chazot G. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch. Neurol. 52:1995;583-588.
110. Bartzokis G., Cummings J.L., Markham C.H., Marmarelis P.Z., Treciokas L.J., Tishler T.A., Marder S.R., Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging. 17:1999;213-222.
111. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 45:1995;1138-1143.
112. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Javoy-Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55:1990;16-20.
113. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Park. Disord. Dement. Sect. 2:1990;327-340.
114. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:1994;876-881.
115. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
116. Double K.L., Maywald M., Schmittel M., Riederer P., Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70:1998;2492-2499.
117. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723.
118. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A. 97:2000;11869-11874.
119. Ben-Shachar D., Riederer P., Youdim M.B. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
120. Andersen J.K. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? Novartis Found. Symp. 235:2001;11-20. [discussion 20-5].
121. Youdim M.B., Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J. Neural. Transm. Suppl. 40:1993;57-67.
122. Pakkenberg B., Moller A., Gundersen H.J., Mouritzen Dam A., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry. 54:1991;30-33.
123. Muthane U., Yasha T.C., Shankar S.K. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann. Neurol. 43:1998;283-287.
124. Kubis N., Faucheux B.A., Ransmayr G., Damier P., Duyckaerts C., Henin D., Forette B., Le Charpentier Y., Hauw J.J., Agid Y., Hirsch E.C. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain. 123(Pt 2):2000;366-373.
125. Gibb W.R., Lees A.J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 54:1991;388-396.
126. Mann D.M., Yates P.O. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21:1983;193-203.
127. Ben-Shachar D., Youdim M.B. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57:1991;2133-2155.
128. Youdim M.B., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126:1989;47-54.
129. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J. Neurochem. 66:1996;2004-2010.
130. Monteiro H.P., Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38:1989;4177-4182.
131. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
132. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723.
133. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994;38-44.
134. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 55:2001;155-164.
135. He Y., Thong P.S., Lee T., Leong S.K., Shi C.Y., Wong P.T., Yuan S.Y., Watt F. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res. 735:1996;149-153.
136. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62:1994;134-146.
137. Oestreicher E., Sengstock G.J., Riederer P., Olanow C.W., Dunn A.J., Arendash G.W. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:1994;8-18.
138. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 10:1999;717-721.
139. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem. J. 340(Pt 3):1999;821-828.
140. Munch G., Luth H.J., Wong A., Arendt T., Hirsch E.C., Ravid R., Riederer P. Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation? J. Chem. Neuroanat. 20:2000;253-257.
141. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054.
142. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267:2000;4904-4911.
143. Yamamoto M., Sakamoto N., Iwai A., Yatsugi S., Hidaka K., Noguchi K., Yuasa T. Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats. Res. Commun. Chem. Pathol. Pharmacol. 81:1993;221-232.
144. Grunblatt E., Mandel S., Maor G., Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78:2001;1-12.
145. Mandel S., Grunblatt E., Youdim M.B. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural. Transm. Suppl. 60:2000;117-124.
146. Slikker W. Jr., Jonas S., Auer R.N., Palmer G.C., Narahashi T., Youdim M.B., Maynard K.I., Carbone K.M., Trembly B. Neuroprotection: past successes and future challenges. Ann. N. Y. Acad. Sci. 939:2001;465-477.